Teppei Hagino

736 total citations
51 papers, 439 citations indexed

About

Teppei Hagino is a scholar working on Dermatology, Immunology and Allergy and Rheumatology. According to data from OpenAlex, Teppei Hagino has authored 51 papers receiving a total of 439 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Dermatology, 23 papers in Immunology and Allergy and 17 papers in Rheumatology. Recurrent topics in Teppei Hagino's work include Dermatology and Skin Diseases (41 papers), Allergic Rhinitis and Sensitization (22 papers) and Urticaria and Related Conditions (16 papers). Teppei Hagino is often cited by papers focused on Dermatology and Skin Diseases (41 papers), Allergic Rhinitis and Sensitization (22 papers) and Urticaria and Related Conditions (16 papers). Teppei Hagino collaborates with scholars based in Japan. Teppei Hagino's co-authors include Hidehisa Saeki, Naoko Kanda, Eita Fujimoto, Sei‐ichiro Motegi, Hiroki Matsuda, Toshihiko Hoashi, Hiroshi Mitsui, Akihiko Uchiyama, Kaori Suzuki and Taeang Arai and has published in prestigious journals such as Frontiers in Immunology, Journal of the American Academy of Dermatology and Journal of Clinical Medicine.

In The Last Decade

Teppei Hagino

42 papers receiving 435 citations

Peers

Teppei Hagino
Eita Fujimoto Japan
Jim S Paik United States
Ricardo Madrigal‐Burgaleta Spain
Luciano Ibba Italy
Esther Barrionuevo Spain
A. Padial Spain
Renata Gontijo Lima United States
Marek L. Kowalski Poland
Marlene Garcia-Neuer United States
M. Issa United States
Eita Fujimoto Japan
Teppei Hagino
Citations per year, relative to Teppei Hagino Teppei Hagino (= 1×) peers Eita Fujimoto

Countries citing papers authored by Teppei Hagino

Since Specialization
Citations

This map shows the geographic impact of Teppei Hagino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Teppei Hagino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Teppei Hagino more than expected).

Fields of papers citing papers by Teppei Hagino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Teppei Hagino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Teppei Hagino. The network helps show where Teppei Hagino may publish in the future.

Co-authorship network of co-authors of Teppei Hagino

This figure shows the co-authorship network connecting the top 25 collaborators of Teppei Hagino. A scholar is included among the top collaborators of Teppei Hagino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Teppei Hagino. Teppei Hagino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2025). Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice. Annals of Dermatology. 37(2). 86–86.
2.
Hagino, Teppei, Akihiko Uchiyama, Sei‐ichiro Motegi, et al.. (2025). 24-Week Real-World Effectiveness and Safety of Lebrikizumab for Atopic Dermatitis in Japan: An Analysis Stratified by Prior Systemic Therapy. Dermatitis. derm20250045–derm20250045. 1 indexed citations
3.
Hagino, Teppei, et al.. (2025). Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan. Dermatitis. derm20250004–derm20250004. 5 indexed citations
4.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2025). Clinical and Laboratory Indexes for Predicting Early and Late Responders to Lebrikizumab in Atopic Dermatitis: A Prospective Cohort Observational Study. Dermatitis. derm20250118–derm20250118. 1 indexed citations
5.
6.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2025). Long‐term real‐world effectiveness of deucravacitinib in psoriasis: A 52‐week prospective study stratified by prior apremilast or biologic therapy. The Journal of Dermatology. 52(4). 634–641. 1 indexed citations
7.
8.
Hagino, Teppei, et al.. (2025). Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis. Dermatitis. 36(6). 627–635. 3 indexed citations
9.
Hagino, Teppei, Akihiko Uchiyama, Hidehisa Saeki, et al.. (2025). Maintenance of Early Responses and Delayed Responses to Tralokinumab Treatment in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Dermatitis. 3456361603–3456361603.
10.
Hagino, Teppei, Akihiko Uchiyama, Hidehisa Saeki, et al.. (2025). A 48-week real-world outcome of tralokinumab treatment for atopic dermatitis: Systemic therapy-naïve versus systemic therapy-experienced patients. Journal of the American Academy of Dermatology. 94(1). 321–322.
11.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Predictive Factors for Long-Term High Responders to Upadacitinib Treatment in Patients with Atopic Dermatitis. Dermatitis. 36(1). 62–71. 8 indexed citations
12.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Effectiveness of long‐term bimekizumab treatment and predictive factors for responders in moderate‐to‐severe psoriasis: A 52‐week real‐world study. The Journal of Dermatology. 52(2). 317–328. 6 indexed citations
13.
Ichiyama, Susumu, Michiko Ito, Taeang Arai, et al.. (2024). Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics. Journal of Nippon Medical School. 91(6). 534–540.
14.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan. Journal of Dermatological Treatment. 35(1). 2307489–2307489. 16 indexed citations
15.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2024). Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study. Journal of Dermatological Treatment. 35(1). 2344591–2344591. 19 indexed citations
16.
Hagino, Teppei, et al.. (2024). Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study. Pharmaceuticals. 17(4). 519–519. 8 indexed citations
17.
Hagino, Teppei, Hidehisa Saeki, & Naoko Kanda. (2023). Biomarkers and Predictive Factors for Treatment Response to Tumor Necrosis Factor-α Inhibitors in Patients with Psoriasis. Journal of Clinical Medicine. 12(3). 974–974. 16 indexed citations
18.
Hagino, Teppei, Hidehisa Saeki, Eita Fujimoto, & Naoko Kanda. (2023). Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib. The Journal of Dermatology. 50(10). 1301–1312. 13 indexed citations
19.
Hagino, Teppei, et al.. (2023). Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis. The Journal of Dermatology. 50(12). 1576–1584. 16 indexed citations
20.
Hagino, Teppei, et al.. (2023). Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis. Clinical Cosmetic and Investigational Dermatology. Volume 16. 3201–3212. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eita Fujimoto Breakdown of academic impact, for papers by Jim S Paik Breakdown of academic impact, for papers by Ricardo Madrigal‐Burgaleta Breakdown of academic impact, for papers by Luciano Ibba Breakdown of academic impact, for papers by Esther Barrionuevo Breakdown of academic impact, for papers by A. Padial Breakdown of academic impact, for papers by Renata Gontijo Lima Breakdown of academic impact, for papers by Marek L. Kowalski Breakdown of academic impact, for papers by Marlene Garcia-Neuer Breakdown of academic impact, for papers by M. Issa
Rankless by CCL
2026